Correction: Medication reconciliation on discharge in a tertiary care Riyadh Hospital: An observational study.

[This corrects the article DOI: 10.1371/journal.pone.0265042.].

Medication Adherence in Palliative Care Patients.

Background In palliative care, therapeutic benefit and desired health outcome might be affected by non-adherence to medications, especially among patients with advanced illnesses, such as cancer. The consequences of non-adherence to medications could include poor health outcomes, recurrent admissions, medication waste, as well as increased morbidity and mortality. The aim of this study was to measure the level of medication adherence in palliative care patients visiting the outpatient clinic at King Fahad Medical City. Methods Inclusion criteria comprised all palliative care patients visiting the outpatient clinic in King Fahad Medical City. Medication adherence was assessed among the participants using the Morisky Medication Adherence Scale (MMAS). Data analysis was conducted using SPSS and GraphPad Prism. Results A total of 84 responses were recorded. Among the respondents, 58.3% were female. The most common underlying diseases among participants were breast cancer. Of the 84 participants, 59 (70.2%) patients reported good adherence, while 25 (29.7%) reported poor adherence. Conclusion Non-adherence to medications among palliative care patients is a significant public health problem. Results indicated that the overall level of medication adherence in palliative care patients was moderate to good. Further studies are required to design new techniques for increasing medication adherence in palliative care patients.

Medication reconciliation on discharge in a tertiary care Riyadh Hospital: An observational study.

The purpose of this study was to assess the frequency and characteristics of discharge medication discrepancies as identified by pharmacists during discharge medication reconciliation. We also attempted to identify the factors that influence the occurrence of drug discrepancies during medication reconciliation. From June to December 2019, a prospective study was performed at the cardiac center of King Fahad Medical City (KFMC), a tertiary care hospital in Riyadh. The information from discharge prescriptions as compared to the medication administration record (MAR), medication history in the cortex system, and the patient home medication list collected from the medication reconciliation form on admission. The study included all adult patients discharged from KFMC's cardiac center. These participants comprised 776 patients, 64.6 percent of whom were men and 35.4 percent of whom were women. Medication discrepancies were encountered in 180 patients (23.2%) out of 776 patients. In regards to the number of discharged medications, 651(83.9%) patients had ≥ 5 medications. Around, 174 (73.4%) discrepancies were intentional, and 63 (26.6%) were unintentional discrepancies. The risk of unintentional medication discrepancy was increased with an increasing number of medications (P-value = 0.008). One out of every four cardiac patients discharged from our hospital had at least one medication discrepancy. The number of drugs taken and the number of discrepancies was found to be related. Necessary steps should be taken to reduce these discrepancies and improve the standard of care.

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades.

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This review summarizes the compound patents and the essential polymorph patents of the PKIs approved by the USFDA from 2001 to 31 May 2021. The dates on the generic drug availability of the PKIs in the USA market have also been forecasted. It is expected that 19 and 48 PKIs will be genericized by 2025 and 2030, respectively, due to their compound patent expiry. This may reduce the financial toxicity associated with the existing PKIs. There are nearly 535 reported PKs. However, the USFDA approved PKIs target only about 10-15% of the total said PKs. As a result, there are still a large number of unexplored PKs. As the field advances during the next 20 years, one can anticipate that PKIs with many scaffolds, chemotypes, and pharmacophores will be developed.

Validity and reliability of the Arabic version of the the EuroQOL (EQ-5D). A study from Saudi Arabia.

OBJECTIVES: The EuroQOL five-dimension questionnaire (EQ-5D) is one of the most widely used tools to evaluate health-related quality of life (HRQOL). Studies on the psychometric features of the EQ-5D in the Gulf region of the Middle East are lacking. This study is aimed at evaluating the validity and reliability of the Arabic version of the EQ-5D in Saudi Arabia. METHODS: The study was done utilizing a convenience sample of Arabic-speaking adult patients or visitors at the outpatient clinic at King Abdulaziz Medical City (KAMC) in Riyadh during October-December 2015. Participants were interviewed using translated into Arabic versions of the EQ-5D and the Short Form Health Survey (SF-36). Known-group construct validity of the EQ-5D and visual analog scale (EQ-VAS) was assessed through testing a number of hypotheses comparing responses to EQ-5D dimensions or EQ-VAS to SF-36 scores by dimension and external variables. Test-retest reliability was also assessed. RESULTS: Eighty subjects were included in the study. Mean ± standard deviartion age was 33.0 ± 11.6 years, with 51% of females. Responses to EQ-5D dimensions revealed that the proportion of respondents reporting problems ranged from 6% for problems with self-care to 48% for pain/discomfort. All of the five hypotheses linking EQ-5D responses to external variables were satisfied. Test-retest reliability was evaluated using Cohen's κ, which ranged from 0.53 to 1.00. CONCLUSION: Validity and reliability of the Arabic EQ-5D were established for evaluating HRQOL in Saudi Arabia. Further studies are warranted to evaluate the validity and reliability of this standard tool in other Arabic-speaking countries with varying cultures.